Key result
VT ablation in severe cardiomyopathy is linked to an ~82% rate of recurrence, LVAD, or transplant.
Why the study?
Procedural and delayed enhancement cardiac magnetic resonance imaging characteristics among patients with very severe cardiomyopathy without left-ventricular assist devices undergoing VT ablation have been incompletely described.
Observational (n=27)
In patients with very severe cardiomyopathy (LVEF < 20%) without LVADs, VT ablation is associated with high rates of VT recurrence and death at midterm follow-up, though DE-CMR can provide localizing information for the arrhythmia.
Answers are grounded in this paper and cite their sources.
High event rates after VT ablation in LVEF <20% warrant caution; leaves open net benefit versus medical therapy.
BACKGROUND: Ablation of ventricular tachycardia (VT) is often performed in patients with structural heart disease. Procedural and delayed enhancement cardiac magnetic resonance imaging (DE-CMR) characteristics among patients with very severe cardiomyopathy (CM) and without left-ventricular assist devices (LVAD) have been incompletely described. OBJECTIVES: To examine procedural and imaging characteristics of patients with very severely decreased ejection fractions undergoing VT ablation procedures. METHODS: Consecutive patients with a left ventricular ejection fraction (EF) < 20% and without LVADs who underwent VT ablation were included. A composite outcome of survival free from VT, LVAD, or transplant was examined. RESULTS: Twenty-seven patients were included (64.1 ± 7.76 years; male n = 23, 88.5%; EF 12.8 ± 3%, LV end diastolic diameter 74 ± 11 mm, ischemic CM (n = 16, 60%), Nonischemic CM (n = 9, 52%), mixed CM (n = 2, 7%)). Twenty-five (93%) patients had failed amiodarone, 9 (33%) had a prior VT ablation, and 13 (48%) underwent ablation for VT storm. Scar was present in 22/23 patients with DE-CMR (intramural [n = 13], endocardial [n = 8], epicardial [n = 2], mixed components [n = 12]). DE-CMR scar corresponded to VT sites of origin in 18/22 patients (82%), excluding one patient with right ventricular VT, two with bundle-branch-reentry VT, and one-non-inducible patient. After 22 ± 19 months, VT occurred in 15/27(56%) patients, death 8/27(30%) and the composite outcome occurred in 22/27(82%) patients. CONCLUSION: Patients with very severe cardiomyopathy undergoing VT ablation represent a high risk population, experiencing high rates of VT recurrence and death on midterm follow up. Despite severe remodeling, DE-CMR provides localizing information on the arrhythmia site of origin.
No takes yet. Share an insight, caveat, or question.
Ghannam et al. (2025) conducted an observational in Ventricular tachycardia with severely decreased left ventricular ejection fraction (n=27). Ventricular tachycardia ablation was evaluated on Composite outcome of survival free from VT, LVAD, or transplant. Ventricular tachycardia ablation in patients with very severe cardiomyopathy was associated with an 82% rate of the composite outcome of VT recurrence, LVAD, or transplant over 22 months.
Synapse has enriched 10 related papers. Consider them for comparative context: